These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 3124536

  • 81. [Comparative study of two immunosuppressive treatment methods in patients with focal segmental glomerulosclerosis].
    Oko A, Idasiak-Piechocka I, Olejnik A, Woźniak A, Lochyńska K, Krzymański M, Salwa-Zurawska W, Czekalski S.
    Pol Arch Med Wewn; 1999 Dec; 102(6):1089-94. PubMed ID: 11072546
    [Abstract] [Full Text] [Related]

  • 82. Treatment of focal segmental glomerulosclerosis.
    Meyrier A.
    Expert Opin Pharmacother; 2005 Aug; 6(9):1539-49. PubMed ID: 16086641
    [Abstract] [Full Text] [Related]

  • 83. [Focal and segmental glomerulosclerosis in Piedmont and the Aosta Valley in Italy: case study and treatment].
    Rollino C, Giacchino F, Savoldi S, Manganaro M, Besso L, Amore A, Ferro M, Quaglia M.
    G Ital Nefrol; 2013 Aug; 30(3):. PubMed ID: 23832471
    [Abstract] [Full Text] [Related]

  • 84. [Current therapeutic possibilities in chronic idiopathic glomerulonephritis].
    Ponticelli C, Fogazzi GB.
    Minerva Urol Nefrol; 1985 Aug; 37(1):9-12. PubMed ID: 3901338
    [No Abstract] [Full Text] [Related]

  • 85. [Cyclosporin in autoimmune diseases].
    Frey FJ.
    Schweiz Med Wochenschr; 1990 May 26; 120(21):772-86. PubMed ID: 2190313
    [Abstract] [Full Text] [Related]

  • 86. The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies.
    Brodehl J.
    Eur J Pediatr; 1991 Apr 26; 150(6):380-7. PubMed ID: 2040345
    [Abstract] [Full Text] [Related]

  • 87. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.
    Ma X, Fang L, Sheng L, Zhou X, Bai S, Zang X, Wang Y, Li M, Lv Z, Zhong Q, Yang X, Wang Y, Hu Y, Yan D, Shi Y, Chen H, Li J, Tao M, Zhuang S, Wang Y, Liu N.
    Ren Fail; 2023 Dec 26; 45(1):2237124. PubMed ID: 37482915
    [Abstract] [Full Text] [Related]

  • 88. An update on the treatment options for focal segmental glomerulosclerosis.
    Meyrier A.
    Expert Opin Pharmacother; 2009 Mar 26; 10(4):615-28. PubMed ID: 19284364
    [Abstract] [Full Text] [Related]

  • 89. Unexplained severe acute kidney injury with rapid recovery of kidney function 11 months later after the start of high-dose steroid therapy.
    Roncone D, Rovin B, Falk R, Nicely C, Nadasdy T, Parikh S, Hebert LA.
    Clin Nephrol; 2014 Aug 26; 82(2):138-43. PubMed ID: 23380388
    [Abstract] [Full Text] [Related]

  • 90. Primary glomerular disease: to treat or not to treat.
    Donadio JV.
    Contrib Nephrol; 1982 Aug 26; 33():86-103. PubMed ID: 7116871
    [No Abstract] [Full Text] [Related]

  • 91. Abatacept experience in steroid and rituximab-resistant focal segmental glomerulosclerosis.
    Jayaraman VK, Thomas M.
    BMJ Case Rep; 2016 Feb 17; 2016():. PubMed ID: 26887886
    [Abstract] [Full Text] [Related]

  • 92. Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors.
    Segarra-Medrano A, Jatem-Escalante E, Agraz-Pamplona I, Carnicer-Cáceres C, Ramos-Terrades N, Ostos-Roldán E, Quiles-Pérez MT, Arbós-Via MA.
    Nefrologia; 2013 Feb 17; 33(4):448-61. PubMed ID: 23897176
    [Abstract] [Full Text] [Related]

  • 93. Minimal change (steroid sensitive) nephrotic syndrome in children: new aspects on pathogenesis and treatment.
    Oh J, Kemper MJ.
    Minerva Pediatr; 2012 Apr 17; 64(2):197-204. PubMed ID: 22495193
    [Abstract] [Full Text] [Related]

  • 94. Long-term Rituximab Therapy in Adult Patients with Idiopathic Nephrotic Syndrome.
    El-Reshaid K, Al-Bader S, Madda JP.
    Saudi J Kidney Dis Transpl; 2022 Apr 17; 33(4):509-515. PubMed ID: 37929543
    [Abstract] [Full Text] [Related]

  • 95. The Immune System and Idiopathic Nephrotic Syndrome.
    Campbell RE, Thurman JM.
    Clin J Am Soc Nephrol; 2022 Dec 17; 17(12):1823-1834. PubMed ID: 36198505
    [Abstract] [Full Text] [Related]

  • 96. Treatment of idiopathic nephrosis by immunophillin modulation.
    Meyrier A.
    Nephrol Dial Transplant; 2003 Aug 17; 18 Suppl 6():vi79-86. PubMed ID: 12953048
    [Abstract] [Full Text] [Related]

  • 97. [Treatment of chronic glomerulonephritis with cytostatics].
    Tareeva IE, Gordovskaia NB, Gladskikh OP, Ivanov AA, Krasnova TN.
    Ter Arkh; 1989 Aug 17; 61(6):9-14. PubMed ID: 2799726
    [Abstract] [Full Text] [Related]

  • 98. Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept
.
    Dado D, Parikh S, Ayoub I, Rovin B, Nadasdy T, Hebert L.
    Clin Nephrol; 2018 May 17; 89(5):376-380. PubMed ID: 29249233
    [Abstract] [Full Text] [Related]

  • 99. Chronic cyclosporine-induced nephrotoxicity in children with steroid-resistant nephrotic syndrome.
    Fujinaga S, Shimizu T.
    Pediatr Nephrol; 2013 Oct 17; 28(10):2065-6. PubMed ID: 23780471
    [No Abstract] [Full Text] [Related]

  • 100. Treatment practices of FSGS among North American pediatric nephrologists.
    Vehaskari VM.
    Pediatr Nephrol; 1999 May 17; 13(4):301-3. PubMed ID: 10454778
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.